|
10 Aug 2020 |
Seres Therapeutics Announces Positive Topline Results from SER-109 Phase 3 ECOSPOR III Study in Recurrent C. difficile Infection
|
|
07 Aug 2020 |
ImmVira and Shanghai Pharma Announce Clinical Collaboration and License Agreement for Commercialization of Novel Intratumoral Oncolytic Virus Immunotherapies
|
|
07 Aug 2020 |
Editas Medicine Regains Full Global Rights to Ocular Medicines
|
|
06 Aug 2020 |
Tessa Therapeutics Announces Results from Two Independent Phase 1/2 Trials of Autologous CD30 CAR-T Cell Therapy in Patients with Relapsed or Refractory Hodgkin Lymphoma
|
|
06 Aug 2020 |
Precigen Triple-Gene Provides Six-month Follow-up Data from Phase I Study of INXN-4001, a Multigenic Investigational Therapeutic Candidate for Heart Failure
|
|
06 Aug 2020 |
Dicerna Announces Positive Clinical Data for Investigational Treatments RG6346 for Chronic Hepatitis B Virus and Nedosiran for Primary Hyperoxaluria, and Presents Preclinical Data Applying RNAi Technology in New Tissues
|
|
04 Aug 2020 |
T-Cure Bioscience Announces Expansion of Collaboration With the National Institutes of Health for T Cell Receptor (TCR) Therapy Targeting HERV-E for the Treatment of Kidney Cancer
|
|
04 Aug 2020 |
REGENXBIO Announces Additional Positive Interim Phase I/IIa Trial Update and Program Updates for RGX-314 for the Treatment of Wet AMD
|
|
04 Aug 2020 |
Novartis announces Kymriah® meets primary endpoint at interim analysis of pivotal study in follicular lymphoma
|
|
03 Aug 2020 |
Cytovia Therapeutics Acquires Worldwide Rights to CytoImmune Therapeutics’ First-In-Class EGFR Dual-targeting CAR for NK Cell Treatment of Glioblastoma & Other Solid Tumors
|
|
03 Aug 2020 |
Alnylam Submits CTA Application for ALN-HSD, an Investigational RNAi Therapeutic for the Treatment of Nonalcoholic Steatohepatitis (NASH)
|
|
30 Jul 2020 |
Bristol Myers Squibb and bluebird bio Announce Submission of Biologics License Application (BLA) to FDA for Idecabtagene Vicleucel (Ide-cel, bb2121) for Adults with Relapsed and Refractory Multiple Myeloma
|
|
29 Jul 2020 |
Arrowhead Pharmaceuticals Earns $20 Million Milestone Payment from Amgen for Start of Phase 2 Trial of AMG 890
|
|
29 Jul 2020 |
Krystal Biotech Announces Initiation of Pivotal Phase 3 Study of Beremagene Geperpavec in Patients with Dystrophic Epidermolysis Bullosa
|
|
27 Jul 2020 |
4D Molecular Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of 4D-110 by Intravitreal Injection for the Treatment of Choroideremia
|
|
27 Jul 2020 |
jCyte Inc. Announces Promising Phase 2b Results of jCell Therapy in Retinitis Pigmentosa
|
|
27 Jul 2020 |
ProMab Presents Promising Results in Humanized CD19 CAR-T Cells Trial
|
|
27 Jul 2020 |
TCR² Therapeutics Announces RECIST Responses with First TC-210 Dose Tested in Advanced Mesothelin-Expressing Solid Tumors
|
|
27 Jul 2020 |
CARISMA Therapeutics Announces FDA Clearance of IND Application for First-Ever Engineered Macrophage Immunotherapy
|
|
25 Jul 2020 |
U.S. FDA Approves Kite’s Tecartus™, the First and Only CAR T Treatment for Relapsed or Refractory Mantle Cell Lymphoma
|
|
23 Jul 2020 |
Encoded Therapeutics Announces $135 Million Series D Financing to Support First Clinical Trials in SCN1A+ Dravet Syndrome and Advance Preclinical Pipeline of Gene Therapies for Debilitating Neurological Disorders
|
|
22 Jul 2020 |
Talaris Therapeutics Announces First Patient Dosed in Phase 3 Clinical Trial of FCR001 in Living Donor Kidney Transplant Recipients
|
|
21 Jul 2020 |
Forge Biologics Launches with $40 Million Series A Financing to Manufacture and Develop Gene Therapies
|
|
21 Jul 2020 |
XyloCor Therapeutics Doses Patients in Phase 1/2 Trial Evaluating Novel Gene Therapy XC001 in Refractory Angina
|
|
21 Jul 2020 |
Vyriad Announces Initiation of Phase 2 Trial in Multiple Cancer Indications
|
